Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	0.38	0.7	0.58
Revenue Growth (YoY)	-	-	-45.49%	20.93%	68.51%
Selling, General & Admin	4.84	3.79	4.34	4.54	2.95
Research & Development	3.96	5.44	4.07	5.11	4.65
Other Operating Expenses	-0.15	-0.03	-0.01	-0.02	-0.02
Total Operating Expenses	8.65	9.2	8.4	9.63	7.58
Operating Income	-8.65	-9.2	-8.01	-8.93	-7
Interest Income	2.39	3.39	0.57	0.5	0.94
Interest Expense	-0.23	-0.17	-0.04	-0.05	-0.04
Total Non-Operating Income (Expense)	2.16	3.22	0.53	0.44	0.89
Pretax Income	-6.49	-5.98	-7.49	-8.49	-6.11
Provision for Income Taxes	-0.11	-0.25	-0.41	-0.83	-0.65
Net Income	-6.38	-5.73	-7.08	-7.66	-5.46
Net Income to Common	-6.38	-5.73	-7.08	-7.66	-5.46
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change (YoY)	1007.68%	1468.08%	539.14%	22.71%	88.02%
EPS (Basic)	-10.00	-100.00	-2000.00	-15500.00	-13600.00
EPS (Diluted)	-10.00	-100.00	-2000.00	-15500.00	-13600.00
Shares Outstanding	2.26	0.07	0.01	0	0
Free Cash Flow	-5.59	-12.27	-6.85	-7.11	-6.33
Free Cash Flow Per Share	-10.19	-247.74	-2169.39	-14387.49	-15712.58
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-2103.41%	-1277.83%	-1210.73%
Profit Margin	-	-	-1858.01%	-1095.28%	-944.64%
FCF Margin	-	-	-1798.43%	-1017.17%	-1094.81%
EBITDA	-8.46	-8.95	-7.73	-8.59	-6.6
EBITDA Margin	-	-	-2029.13%	-1228.76%	-1141.00%
EBIT	-8.65	-9.2	-8.01	-8.93	-7
EBIT Margin	-	-	-2103.41%	-1277.83%	-1210.73%
Effective Tax Rate	1.62%	4.18%	5.42%	9.80%	10.58%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q